Chong-Jen Yu

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 87 Citations 28,365 676 World Ranking 8742 National Ranking 16

Overview

What are the main themes of his work throughout his whole career to date

Much of his study explores Internal medicine relationship to Cohort study. Chong-Jen Yu conducts interdisciplinary study in the fields of Cancer and Pathology through his research. His Pathology study frequently intersects with other fields, such as Lung cancer. In his study, Chong-Jen Yu carries out multidisciplinary Lung cancer and Performance status research. In his research, Chong-Jen Yu performs multidisciplinary study on Performance status and Cancer. Chong-Jen Yu performs integrative study on Gefitinib and T790M in his works. With his scientific publications, his incorporates both T790M and Erlotinib. Chong-Jen Yu performs integrative Erlotinib and Afatinib research in his work. In his papers, Chong-Jen Yu integrates diverse fields, such as Afatinib and Gefitinib.

Chong-Jen Yu most often published in these fields:

Internal medicine (100.00%)
Cancer (75.00%)
Lung cancer (75.00%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

James Bean;Cameron Brennan;Jin-Yuan Shih;Gregory Riely.
Proceedings of the National Academy of Sciences of the United States of America (2007)

1745 Citations

MicroRNA Signature Predicts Survival and Relapse in Lung Cancer

Sung Liang Yu;Hsuan Yu Chen;Hsuan Yu Chen;Gee Chen Chang;Chih Yi Chen.
Cancer Cell (2008)

955 Citations

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Jean-Charles Soria;Daniel S W Tan;Rita Chiari;Yi-Long Wu.
The Lancet (2017)

919 Citations

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

James C.H. Yang;Lecia V. Sequist;Sarayut Lucien Geater;Chun Ming Tsai.
Lancet Oncology (2015)

842 Citations

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.

Yi-Long Wu;Masahiro Tsuboi;Jie He;Thomas John.
The New England Journal of Medicine (2020)

596 Citations

Value of sonography in determining the nature of pleural effusion: analysis of 320 cases.

Pan-Chyr Yang;Kwen-Tay Luh;Dun-Bing Chang;Huey-Dong Wu.
American Journal of Roentgenology (1992)

588 Citations

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

Tony S.K. Mok;Yi-Long Wu;Jin Soo Lee;Chong-Jen Yu.
Clinical Cancer Research (2015)

526 Citations

Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

Jenn-Yu Wu;Chong-Jen Yu;Yeun-Chung Chang;Chih-Hsin Yang.
Clinical Cancer Research (2011)

437 Citations

Mycobacterium abscessus Complex Infections in Humans.

Meng-Rui Lee;Wang-Huei Sheng;Chien-Ching Hung;Chong-Jen Yu.
Emerging Infectious Diseases (2015)

377 Citations

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial

Yi Long Wu;Jin Soo Lee;Sumitra Thongprasert;Chong Jen Yu.
Lancet Oncology (2013)

377 Citations

If you think any of the details on this page are incorrect, let us know.